Statement of Principles concerning peripheral neuropathy (Reasonable Hypothesis) (No. 72 of 2023)

The instrument centres on three core legal‑medical concepts: the defined medical entity, the set of qualifying factors that raise a reasonable hypothesis of connection to service, and the relationship of those factors to "relevant service".

1. Defined medical entity: Peripheral neuropathy is defined in structured terms (s 7(2)). The definition contains three limbs: non‑traumatic pathology of peripheral nerves to upper or lower limbs; clinical expression by both symptoms and either signs or electrodiagnostic evidence; and functional impact on motor, sensory or autonomic systems (s 7(2)(a)(i)-(ii)). The Schedule clarifies "non‑traumatic" by listing excluded mechanisms such as blunt, penetrating, compression, traction and thermal trauma, electrical trauma, ionising radiation and entrapment (Schedule 1).

2. Exclusions: The SoP explicitly excludes several named diseases and syndromes from the definition (s 7(2)(c)). These include autoimmune nodopathies associated with nodal/paranodal autoantibodies, chronic inflammatory demyelinating polyneuropathy (CIDP) and its variants, Guillain-Barré syndrome, hereditary neuropathies, isolated mononeuropathies such as carpal tunnel syndrome, motor neurone disease (ALS), neurogenic thoracic outlet syndrome, complex regional pain syndrome, and peripheral manifestations of central nervous system pathology (s 7(2)(c)(i)-(xii)). These exclusions determine the scope of the SoP and thereby channel which clinical entities are adjudicated under this instrument.

3. Factors and causal threshold: Section 8 articulates the RMA’s view that there is "sound medical‑scientific evidence" indicating peripheral neuropathy and death from peripheral neuropathy can be related to relevant service. Section 9 is the operational core: it specifies an extensive list of factors that, if present at the time of clinical onset or clinical worsening, are sufficient in the RMA’s view to raise the reasonable hypothesis that the neuropathy is connected with service. Factors range across medical comorbidities (amyloidosis, chronic liver disease, chronic renal failure, sarcoidosis), specified infections, haematological or lymphoproliferative disorders, malignant neoplasms and paraneoplastic syndromes, severe alcohol or substance use disorders (defined to DSM‑5‑TR derived criteria in the Schedule), nutritional deficiencies, specified drug exposures (with separate lists for drugs that cannot be ceased or substituted), particular toxic exposures (short‑term and long‑term lists with ppm or dose thresholds in the Schedule), acute poisonings, bariatric surgery, cisplatin chemotherapy within a six month window, stem cell/bone marrow transplantation, and inability to obtain appropriate clinical management (ss 9(1)-(62), Schedule 1).

4. Temporal and quantitative thresholds: Many items are tightly specified by timing and dose or frequency. Examples include: critical illness within 30 days prior to onset/worsening (ss 9(12), 9(42)); cisplatin within six months (ss 9(27), 9(57)); bariatric surgery within five years (ss 9(28), 9(58)); organophosphorus or carbamate acute cholinergic poisoning within two months (ss 9(19), 9(49)); exposure to a TCDD‑contaminated agent within 30 days (ss 9(18), 9(48)); alcohol consumption of at least 200 kilograms within 10 years (ss 9(14), 9(44)) with the Schedule noting that alcohol consumption should be calculated using the Australian Standard of 10 grams per standard drink (Schedule 1 note). Chemical exposure thresholds for short and long term are detailed numerically in the Schedule (e.g. n‑hexane inhaled concentration >0.6 ppm for both short and long term lists, but the frequency and duration requirements differ).

5. Relationship to service: The SoP does not automatically attribute causation; for a factor to raise the reasonable hypothesis it must be related to the person’s relevant service (s 10(1)). Further, a distinct rule applies to factors listed in ss 9(32)-9(62): they only apply to material contribution to, or aggravation of, peripheral neuropathy where the neuropathy was suffered or contracted before or during (but did not arise out of) the person’s relevant service (s 10(2)). This distinction separates factors relevant to initial onset from those applicable to material contribution or aggravation for pre‑existing conditions.

6. Cross‑SoP referencing: If a factor in section 9 refers to an injury or disease that is the subject of another SoP, the factors within that other SoP apply according to that instrument’s terms as in force from time to time (s 11). The Schedule contains the lists and technical definitions that operationalise many of the factors referred to in section 9.

These conceptual foundations determine the evidence that claimants must assemble and the limits on adjudication by decision makers. The SoP converts particular medical states, exposures and temporal relationships into mechanical triggers for the "reasonable hypothesis" standard referenced in the VEA/MRCA claim process (s 8-9, Schedule 1).

This instrument affects three principal groups directly and several others indirectly, as determined by its terms.

1. Veterans, former members and serving members with relevant service who are making claims: The SoP applies to claims "to which section 120A of the VEA or section 338 of the MRCA applies" (s 5). That cohort includes persons whose entitlements are adjudicated under those statutory provisions. For each such claimant who asserts peripheral neuropathy or death from peripheral neuropathy, the SoP sets out the medical criteria and the factor list that the decision maker will use at the reasonable hypothesis threshold.

2. Decision makers and medical officers who adjudicate claims under the VEA and MRCA: The RMA determined the SoP under s 196B(2) of the VEA (s 3). The instrument therefore functions as the RMA’s medical standard for the reasonable hypothesis test. Those operating the claims system must apply this SoP when considering whether the required causal threshold is met for peripheral neuropathy claims within the specified statutory provisions (s 5; s 8-9).

3. Treating clinicians and medico‑legal experts preparing evidence: The diagnosis requirement (symptoms plus signs or electrodiagnostic evidence; s 7(2)(a)) and the detailed lists and timing windows in section 9 and the Schedule mean that clinicians furnishing certificates, diagnostic reports, laboratory data, EMG/nerve conduction study reports, medication histories and exposure histories will be directly engaged. The instrument’s definitions of "severe alcohol use disorder", "severe substance use disorder", nutritional deficiencies, organophosphate poisoning, and chemical exposure thresholds mandate particular clinical or biochemical evidence to be produced (Schedule 1).

4. Dependants and estates in death claims: The SoP includes "death from peripheral neuropathy" as within scope (s 7(3)), defined to include terminal events or conditions to which peripheral neuropathy contributed (Schedule 1). Where death is the subject of a claim, dependants or estates who seek a finding that death was caused by or contributed to by peripheral neuropathy will be affected by the definitions and factor lists.

5. Administrators of exposure and occupational records: The SoP requires evidence of exposures that may go back many years (e.g. long‑term chemical exposure, bariatric surgery within five years, long‑term drug therapy). Employers, occupational health record keepers, pharmacy records and military exposure logs will be relevant to meeting the specified criteria. The Schedule identifies discrete activities that meet the definition of exposure to TCDD‑contaminated agents (decanting, spraying, cleaning equipment used to apply, being sprayed with, handling/ sawing treated timber, being in dust from treated timber, using contaminated cutting oils) and specific chemical lists (Schedule 1).

6. Interacting SoP regimes: Section 11 expressly requires that, where a factor in this SoP refers to another injury or disease covered by a different SoP, the terms of that other SoP apply. Thus persons and professionals engaged in claims where comorbid conditions are at issue will need to consult multiple SoPs as the RMA updates them.

Indirectly, the instrument affects administrative costs and workload across the claims system. The combination of precise diagnostic requirements, discrete exposure thresholds and numerous specified lists will tend to increase the volume and specificity of medical and documentary evidence that applicants must provide and that decision makers must examine.

Who pays and who decides, as laid down by the instrument, are these: the Repatriation Medical Authority determined the SoP (s 3) and the SoP applies to claims made under the specified sections of the VEA and MRCA (s 5). The instrument does not itself authorise payment or create entitlements; it is a medical standard applied within the statutory adjudication frameworks.

The instrument does not create new statutory duties in the criminal or regulatory sense; rather, it prescribes medical definitions and causal factors that operate as evidential triggers for statutory decision making under the VEA and MRCA. The key duties and rights it frames are administrative and evidentiary.

Duties (to be performed implicitly by various actors)

• Duty of decision makers to apply the SoP where appropriate: The SoP is determined by the RMA under s 196B(2) of the VEA (s 3) and applies to claims falling within specified statutory provisions (s 5). Decision makers adjudicating such claims are required in practice to consider the SoP’s content when assessing whether a reasonable hypothesis of service connection is raised. The instrument itself sets the medical standard but does not set procedural steps; those are governed by the VEA/MRCA.

• Duty of claimants (practical evidential duty): To rely on any factor in s 9, the claimant must establish the factor existed at the relevant time (clinical onset or worsening) and that it is related to relevant service (s 10(1)). Many factors in s 9 require clinical, haematological or biochemical demonstration (for example specified agents under s 9(20) require clinical, haematological or biochemical evidence; Schedule 1 contains the lists and diagnostic criteria). For drug‑related factors requiring improvement on withdrawal or redevelopment on rechallenge, the claimant must provide evidence of the temporal relationship and the clinical response (ss 9(24), 9(26), 9(54), 9(56)).

• Duty to establish timing and relationship to service: The instrument conditions the sufficiency of listed factors on their being "related to the relevant service rendered by the person" (s 10(1)). For factors listed in ss 9(32)-9(62), these apply only to claims of material contribution or aggravation where peripheral neuropathy was suffered or contracted before or during (but did not arise out of) relevant service (s 10(2)). Practically, this imposes an evidential obligation to assemble historical medical records and service records that demonstrate timing.

Rights (as articulated or implied by the instrument)

• Right to rely on the RMA’s SoP as the medical standard for the reasonable hypothesis test: The SoP sets out which clinical states and exposures, when proven and related to relevant service, meet the RMA’s threshold that "a reasonable hypothesis has been raised" connecting the condition with service (ss 8-9). Claimants therefore have the right to have adjudicators consider the SoP in their claim assessment for peripheral neuropathy.

• Right to cross‑reference other SoPs: If a factor in s 9 refers to an injury or disease subject to another SoP, the claimant can rely on the factors set out in that other SoP as in force from time to time (s 11). That is, the instrument incorporates other SoPs by reference when relevant.

• Right to inclusion of death claims: The SoP explicitly covers "death from peripheral neuropathy" where death was contributed to by the person’s neuropathy (s 7(3)); dependants or estates making such claims may rely on the SoP for the causal link.

Operational implications of the duties and rights

• The SoP reallocates practical duties to assemble diagnostic and exposure evidence onto claimants and their medical advisers; the Schedule’s numerical thresholds and DSM‑5‑TR‑derived diagnostic criteria frame what evidence is necessary (Schedule 1). For example, demonstrating "severe alcohol use disorder" requires showing at least six DSM‑5‑TR‑derived criteria within a 12‑month period per Schedule 1.

• The instrument requires precise forensic medical documentation: EMG/nerve conduction study reports, clinical signs, biochemical markers, drug histories, evidence of improvement after drug cessation or re‑challenge, quantified chemical exposure records (with ppm or dose thresholds), and service‑linked exposure records.

• Administrative duty of coherence across SoPs: Where other SoPs are implicated (s 11), decision makers must reconcile the factor lists and definitions across multiple RMA instruments as they change over time.

The instrument itself does not specify appeals, procedural rights, or penalties. Those procedural elements remain within the VEA and MRCA frameworks to which this SoP applies (s 5). The SoP sets the medical and evidentiary parameters that feed into those statutory procedures.

The Statement of Principles is a technical medical instrument and does not itself impose criminal penalties, fines, or direct regulatory sanctions. The text contains no penal provisions, enforcement mechanisms or administrative sanctions. Its operative effect is evidentiary and definitional within the statutory claims framework established by the VEA and the MRCA.

How enforcement works in practice, as implied by the instrument

• No penalties within the SoP: There are no sections in the instrument that create offences, monetary penalties or compliance orders. The SoP provides medical criteria and lists for use in claims (ss 7-11; Schedule 1). It does not purport to compel conduct outside the claims process.

• Role in adjudication and outcome consequences: The practical “enforcement” role of the SoP is its use by decision makers when deciding whether a claim meets the reasonable hypothesis threshold and therefore whether a claim proceeds to the next evidentiary stage or succeeds under the relevant entitlement schemes. The instrument applies to claims under s 120A of the VEA or s 338 of the MRCA (s 5); legislative processes in those Acts determine the entitlements or liabilities that flow from a successful claim. The SoP informs the medical causation conclusion that is a precondition to statutory benefits or compensation, but it does not itself award or enforce benefits.

• Evidential thresholds and administrative outcomes: The SoP creates mechanical tests that, if met and related to service, satisfy the RMA’s view of the medical evidence necessary to raise a reasonable hypothesis (ss 8-9). Administrative decisions that rely on the SoP may result in grant or denial of entitlements under the VEA/MRCA; any appeal or review of such decisions will occur within the procedural avenues provided by those Acts and by the administrative review bodies they create. The SoP does not set, nor does it alter, the appeal routes or sanctions.

• Interaction with other SoPs: Section 11 requires application of factors in other SoPs where a listed factor in this SoP refers to an injury or disease that is covered by another SoP. Enforcement in such cases depends on applying the other instrument’s terms "as in force from time to time". The practical implication is that decision makers must apply the current medical standards across instruments; there is no on‑its‑face enforcement mechanism beyond administrative application.

Potential indirect enforcement effects and consequences

• Evidence production pressure: Because the instrument sets specific and sometimes demanding evidentiary criteria (electrodiagnostic testing, biochemical confirmation, documented exposures with ppm/dose values, temporal windows for onset or worsening), claimants who cannot marshal the specified evidence may be at increased risk of adverse decisions. This is not a penalty in the statutory sense, but it is an outcome consequence.

• Cross‑instrument shifts: Repeal of the earlier 2014 SoP (s 4) and introduction of the new instrument may change what evidence is sufficient. Decision makers applying updated SoPs may reach different outcomes than under prior versions. The instrument itself provides no remedial or transitional enforcement provisions; those are governed by the enabling statutes and policy practices.

In summary, penalties and formal enforcement powers are not contained in the SoP. The instrument’s effect is to create a medical standard that, when applied within the VEA and MRCA claim processes, influences administrative outcomes that can have significant financial or other consequences for claimants, dependants and estates. Any formal enforcement or penalties will be those embedded in the VEA/MRCA and not within this SoP.

The instrument is made under the authority of subsection 196B(2) of the VEA (s 3) and explicitly applies only to claims that fall within section 120A of the VEA or section 338 of the MRCA (s 5). Consequently, the SoP is an instrument that functions within the legal architecture of those statutes; its operational effect is entirely derivative of that statutory context.

Direct statutory interactions

• Foundational statutory authority: The RMA’s authority to determine Statements of Principles derives from the VEA. This instrument was made under that authority (s 3). Its determinations are therefore legal instruments that feed into the claim processes set up by the VEA and the MRCA.

• Application to specified claim provisions: The instrument expressly states its application is to claims to which s 120A of the VEA or s 338 of the MRCA applies (s 5). The content of those provisions in the Acts determines which claims this SoP will inform. The SoP does not alter the statutory tests for entitlement in those Acts; it sets out the medical factors which the RMA regards as sufficient to raise a reasonable hypothesis within those statutory frameworks.

Interaction with other Statements of Principles

• Cross‑SoP dependency: Section 11 provides that where a factor in this SoP refers to an injury or disease that is the subject of another SoP determined under s 196B(2) of the VEA, then the factors in that other SoP "apply in accordance with the terms of that Statement of Principles as in force from time to time" (s 11). Practically, this requires decision makers and claimants to consult and reconcile multiple SoPs. The interplay is temporal: the current terms of the other SoP apply at the time of adjudication, which can create shifting evidentiary expectations if another SoP is amended.

Evidential and procedural interactions

• Evidence required by the SoP supports statutory causation tests: The diagnosis requirements (s 7(2)), temporal windows and exposure thresholds in section 9 and the Schedule will be used by decision makers under the VEA and MRCA to determine whether the statutory causation threshold (reasonable hypothesis) is met. The SoP effectively operationalises medical causation standards for the statutory process, but it does not alter the procedural steps for filing, reviewing or appealing claims that are embedded in the VEA/MRCA.

• Dependence on other statutory records and evidence: Many factors require documented exposure histories, medication records, surgical records, biochemical and haematological reports, and electrodiagnostic testing. These records are produced in other regulatory and occupational contexts (military service records, employment health records, hospital and pharmacy records). The SoP’s practical effect is to require that evidence from those other legal and administrative regimes be brought into the statutory claims process.

Limits of interaction

• No amendment to entitlements or procedure in this instrument: The SoP does not change the entitlements, benefits, appeal rights or procedural rules set out in the VEA or the MRCA. It provides the medical standard used in the context of those bodies of law.

• No criminal or civil law extension: The SoP does not create independent civil liabilities or criminal offences. It does not affect other legal regimes (workers compensation, general civil tort law, criminal law) directly; however, evidence assembled for an SoP‑based claim may be relevant in other proceedings, but that effect is not governed by this instrument.

Potential practical frictions

• Temporal inconsistency across SoPs: Because s 11 requires reliance on other SoPs "as in force from time to time", and the RMA may update other SoPs independently, a claimant dealing with multiple comorbid conditions may need to navigate differing evidentiary standards that have changed since the date of service or earlier claims. This can create coordination costs in assembling contemporaneous or retrospective medical proof.

• Overlap with occupational exposure registries and record systems: The detailed chemical and exposure lists in the Schedule will require integration of military occupational exposure records (if any), employer records and clinical documentation. The SoP therefore interacts operationally with record‑keeping regimes that sit outside the VEA/MRCA.

Overall, the instrument is an internal component of the VEA/MRCA claim ecology: a medical‑technical instrument with no independent enforcement outside its use in those statutes, and with explicit cross‑referencing to other RMA SoPs that may alter evidentiary expectations over time.

This instrument contains limited internal amendment history and records only the repeal of the prior SoP. The operative lines in the text that bear on amendment are these.

• Repeal of the 2014 instrument: Section 4 states that "The Statement of Principles concerning peripheral neuropathy No. 74 of 2014 (Federal Register of Legislation No. F2014L01135) made under subsection 196B(2) of the VEA is repealed." That is the sole expressed repeal or amendment recorded in the instrument itself. The new instrument replaces the 2014 iteration as the RMA’s current SoP for peripheral neuropathy.

• Commencement date: The instrument commences on 25 July 2023 (s 2). Any amendments effected by this instrument take legal effect from that date.

• Cross‑instrument change mechanism: Section 11 provides that if a factor in this SoP refers to an injury or disease that has a separate SoP, then the factors in that other SoP apply "as in force from time to time". This creates an explicit channel by which changes to other SoPs will alter how this SoP is applied when such cross‑referencing occurs. In practical terms, therefore, the application of this instrument is partially dynamic with respect to other SoPs.

What the instrument does not record

• No staged amendment log is included: The instrument does not include a schedule of prior amendments beyond the repeal of the 2014 instrument, nor is there a transitional provision or saving clause in the text to address claims in progress at the time of commencement.

• No internal amendment procedure or sunset provision: The instrument does not state a review date, sunset clause, or procedure for modification beyond the RMA’s power under s 196B(2) of the VEA to determine SoPs. Future changes would be recorded in subsequent instruments or in the Federal Register of Legislation.

Practical consequences of the amendment history

• Replacement effect: The 2014 instrument is expressly repealed (s 4). Claimants, medical advisers and decision makers need to apply the 2023 SoP for claims covered by s 120A of the VEA and s 338 of the MRCA from the commencement date (s 2). This may change the set of factors that suffice to raise a reasonable hypothesis and may affect claims previously adjudicated under the 2014 instrument.

• Dynamic interaction with other SoPs: Because the instrument relies on "as in force from time to time" application of other SoPs (s 11), future amendments to other SoPs will affect the application of this instrument in cases where cross‑referencing occurs.

• No recorded transitional arrangements: The absence of transitional wording in the instrument suggests that claims will be assessed under the new SoP from commencement, absent any statutory transitional rules in the VEA or MRCA or policy directions issued by administering agencies. The instrument itself does not state transitional handling for pending claims or appeals.

In sum, the amendment history within this instrument is limited to repealing the earlier RMA SoP and bringing the new instrument into force. The instrument sends users to other, separately maintained SoPs where cross‑referencing applies and thereby creates an ongoing dependence on future amendments to those instruments.

The instrument itself does not record any litigation history. It contains no references to judicial decisions, appeals, or litigation involving the 2014 or prior Statements of Principles. The only procedural history recorded within the text is the repeal of the 2014 SoP (s 4) and the making of the new SoP on 23 June 2023, with commencement on 25 July 2023 (s 2 and the instrument date).

What the instrument discloses and what it does not

• No internal record of court challenges or reviews: The instrument contains no notation of prior litigation about its content or the RMA’s determinations. It does not purport to summarise case law or administrative review outcomes relating to claims for peripheral neuropathy.

• Repeal of prior instrument as administrative history only: The repeal of the 2014 instrument is an administrative action recorded in s 4. The text does not say whether the repeal was a response to litigation, changed medical science, policy review, or routine update.

Practical approach for practitioners

• Instrument is silent on litigation: Because the instrument includes no litigation history, practitioners must assume that assessing the way tribunals or courts have treated peripheral neuropathy claims will require external legal research beyond the text of this instrument. The SoP itself is a medical instrument; how courts or review bodies have treated RMA SoPs, specific factors, or the reasonable hypothesis test is not addressed in the instrument.

• Repeal does not equal settled litigation posture: The change from the 2014 instrument to the 2023 instrument may have been prompted by developments in medical evidence, policy or administrative practice. The instrument does not document those drivers. Where litigation is contemplated or current, parties should consider the likely legal questions implicated by changes in SoP content, but the instrument does not supply that jurisprudential material.

In short, the instrument provides no litigation history. It replaces the 2014 SoP but does not say whether, or how, prior decisions or judicial interpretations of the RMA’s earlier instrument will influence application of the new SoP. For litigation history and precedents, claimants and advisers must look outside this instrument to the VEA and MRCA administrative and judicial record.

This instrument contains many technical definitions, temporal windows and list‑based thresholds that create sharp evidential and procedural pitfalls. The following are concrete "gotchas" extracted from the instrument that practitioners and claimants frequently need to be aware of.

1. Diagnosis requires signs or electrodiagnostic evidence, not only symptoms: The definition of peripheral neuropathy requires symptoms and either signs or electrodiagnostic evidence (EMG or nerve conduction studies) of impaired motor, sensory or autonomic functioning (s 7(2)(a)(i)-(ii)). A claimant who presents only with subjective symptoms such as tingling or numbness without documented signs or electrophysiological studies risks falling short of the instrument’s diagnostic gate.

2. Multiple named exclusions narrow scope: Section 7(2)(c) lists a set of exclusions (autoimmune nodopathies associated with nodal/paranodal autoantibodies; CIDP; Guillain‑Barré; hereditary neuropathies; isolated mononeuropathies such as carpal tunnel; motor neurone disease; neurogenic thoracic outlet syndrome; peripheral manifestations of brain or spinal cord pathology; complex regional pain syndrome; multifocal motor neuropathy; neuralgic amyotrophy). If the claimant’s condition is one of these, it is outside this SoP and must be addressed as a separate clinical entity (s 7(2)(c)).

3. Different factor sets for onset versus worsening and different applicability for pre‑existing neuropathy: Factors listed at s 9(1)-(31) apply to the clinical onset. Factors at s 9(32)-(62) apply to clinical worsening. Critically, ss 9(32)-(62) apply only to material contribution to, or aggravation of, peripheral neuropathy where the neuropathy was suffered or contracted before or during (but did not arise out of) relevant service (s 10(2)). In short, if neuropathy arose out of service, the later factors may not be the operative pathway for material contribution/aggravation.

4. Tight temporal windows and frequency/dose thresholds: Many factors have firm temporal limits and quantitative thresholds. Examples:

   • Acute cholinergic poisoning from organophosphorus compounds or carbamate within two months before clinical onset/worsening (ss 9(19), 9(49)); the Schedule defines acute cholinergic poisoning symptoms.

   • Cisplatin within six months before onset/worsening (ss 9(27), 9(57)).

   • Bariatric surgery within five years before onset/worsening (ss 9(28), 9(58)).

   • Critical illness within 30 days before onset/worsening (ss 9(12), 9(42)); Schedule defines critical illness.

   • Chemical exposures listed as short term require at least 30 occasions within a continuous six month period before onset/worsening and, if exposure ceased before onset/worsening, the onset/worsening must occur within three months of cessation (ss 9(15), 9(45); Schedule contains chemical lists and dose/ppm thresholds).

   • Long term chemical exposures require "on more days than not" for at least one year before onset/worsening and, if exposure ceased prior, onset/worsening must occur within three months of cessation (ss 9(16), 9(46); Schedule contains chemicals and threshold concentrations).

Failure to align evidence with the precise temporal and quantitative prescriptions will undermine reliance on the factor.

5. Alcohol threshold is unusually high but must be demonstrated: The instrument specifies "consuming at least 200 kilograms of alcohol within the 10 years before the clinical onset" (s 9(14)) and repeats it for worsening (s 9(44)). The Schedule notes alcohol consumption is calculated using the Australian Standard of 10 grams per standard alcoholic drink. Concretely, 200 kg = 200,000 grams / 10 g = 20,000 standard drinks over ten years, i.e. an average of approximately 5.5 standard drinks per day over ten years. Claimants must be able to substantiate consumption at that magnitude to use this factor.

6. Drug lists and "cannot be ceased or substituted" distinction: The Schedule distinguishes between "specified list of drugs" (a long list including platinum compounds, taxanes, statins, fluoroquinolones etc.) and "specified list of drugs that cannot be ceased or substituted" (a separate list including interferons, lithium, some antiretrovirals, certain chemotherapeutic agents, etc.). For drugs that "cannot be ceased or substituted", the mere taking of the drug at the time of clinical onset or worsening is a listed factor (ss 9(23), 9(53)), whereas other drug factors require either that the drug be from the specified list (ss 9(25), 9(55)) or that there be individual evidence of association in the person plus improvement on cessation or reproducibility on rechallenge (ss 9(24), 9(26), 9(54), 9(56)). Documenting the medication history, the clinical course on withdrawal and any rechallenge data is therefore essential.

7. TCDD contamination is activity‑based and chemically specific: The Schedule defines exposure to an agent contaminated by 2,3,7,8‑TCDD by reference to particular activities (decanting, spraying, cleaning/maintaining equipment used to apply, being sprayed with, handling or sawing treated timber, being in dust from treated timber, using contaminated cutting oils) and enumerates the chemicals that, if present, constitute the contamination list (Schedule 1). A claimant must show the specific activity and the specific chemical exposure within 30 days prior to onset/worsening (ss 9(18), 9(48)), not merely an asserted presence of dioxin.

8. "Inability to obtain appropriate clinical management" as a factor for worsening: Section 9(62) lists "inability to obtain appropriate clinical management for peripheral neuropathy before the clinical worsening" as a factor for worsening. This is a potentially fact‑sensitive and subjective element that will require contemporaneous medical records demonstrating inability to access care, and may raise proof difficulties.

9. Cross‑SoP dependencies can change the case law and evidential landscape: Section 11 makes some factors dependent on other SoPs "as in force from time to time". If a factor in s 9 references a disease subject to another SoP, the terms of that other SoP govern the factor’s application. This can complicate case preparation where multiple diseases or exposures are in play and where other SoPs have been updated.

These technical traps highlight that success under this SoP turns on meticulous, contemporaneous, and quantifiable medical, exposure and service record evidence aligned to the instrument’s timing and definitional requirements.

Compliance, in the context of this Statement of Principles, means assembling and presenting the specific medical and documentary evidence the SoP requires so that a decision maker can find a reasonable hypothesis that peripheral neuropathy (or death from it) is related to relevant service. The following is a practical, source‑grounded checklist and procedural note set that follows the instrument.

1. Establish the diagnosis according to the SoP’s definition (s 7(2))

   • Ensure documentation of both symptoms and either clinical signs or electrodiagnostic evidence. Symptoms include tingling, numbness, pain, weakness and sweating dysfunction (Note 2 to s 7(2)). Signs to be recorded by treating clinicians should include objective neurological findings consistent with peripheral nerve dysfunction. If electrodiagnostic evidence is absent, arrange EMG and nerve conduction studies and include study reports.

   • Confirm that the neuropathy is non‑traumatic per the Schedule: demonstrate that the mechanism is not blunt, penetrating, compression, traction, thermal, electrical trauma, ionising radiation, effect of a space occupying lesion, or entrapment of a nerve or root (Schedule 1 definition of "non‑traumatic").

   • Check the exclusion list (s 7(2)(c)). If the clinical entity is among the enumerated exclusions (for example CIDP, Guillain‑Barré, hereditary neuropathies, isolated mononeuropathies like carpal tunnel), that condition is not within the scope of this SoP; consider whether another SoP or different statutory pathway is relevant.

2. Map the clinical onset and/or clinical worsening dates precisely

   • The SoP’s factors are time‑bound (e.g. cisplatin within six months, bariatric surgery within five years, critical illness within 30 days, organophosphate poisoning within two months). Prepare a timeline that anchors the date of clinical onset and any dates of clinical worsening to medical records and service records.

   • For pre‑existing neuropathy, remember the distinct rule in s 10(2): factors in ss 9(32)-9(62) only apply to material contribution or aggravation where neuropathy was suffered or contracted before or during (but did not arise out of) relevant service. Establish whether the neuropathy was new, arose out of service, or pre‑existed service.

3. Demonstrate the presence of at least one listed factor related to relevant service (ss 8-9; s 10(1))

   • Review section 9 in full and the Schedule’s lists. Identify which factor(s) could be relevant to your client. These include medical comorbidities (amyloidosis, chronic liver disease, chronic renal failure, sarcoidosis), infections (Schedule list), haematological disorders (Schedule list), listed drugs or drugs that cannot be ceased or substituted, quantified chemical exposures (short or long term lists with thresholds), severe alcohol or substance use disorder (Schedule DSM‑5‑TR derived criteria), nutritional deficiencies (Schedule list), specific poisonings and other iatrogenic causes (cisplatin, stem cell transplantation, bariatric surgery, hypophosphataemia with TPN).

   • For chemical exposures consult the Schedule for numeric thresholds and frequency/duration requirements. For short term chemical exposures you must show exposure on at least 30 occasions within a continuous six month period before onset/worsening and, if exposure ceased before onset/worsening, onset/worsening must have been within three months after cessation (ss 9(15), 9(45); Schedule lists and thresholds). For long term chemical exposure you must show exposure on more days than not for at least one year before onset/worsening (ss 9(16), 9(46); Schedule).

   • When asserting drug causation factors that require reproducibility or improvement after discontinuation, supply evidence of the temporal relationship and clinical response. For drugs where the Schedule identifies them as drugs "that cannot be ceased or substituted" (e.g. interferons, lithium, some antivirals, certain chemotherapeutics), provide prescription records showing the drug was being taken at the time of onset/worsening (ss 9(23), 9(53)).

4. Quantify alcohol or substance exposure where relied upon

   • If relying on "consuming at least 200 kilograms of alcohol within the 10 years before the clinical onset" (s 9(14)) or worsening (s 9(44)), translate reported consumption into grams and standard drinks using the Schedule note: the Australian Standard is 10 grams per standard drink. 200 kg of pure alcohol equals 200,000 grams, which equals 20,000 standard drinks in total over ten years. Produce corroborating records where possible , usual records include medical notes, treatment records for alcohol use disorder, employment records, or affidavits with corroboration.

   • If relying on severe substance use disorder, ensure documentation meets the DSM‑5‑TR‑derived criteria listed in the Schedule (at least six criteria within 12 months). Obtain psychiatric assessments or addiction medicine reports consistent with those criteria.

5. Assemble biochemical, haematological and occupational evidence

   • For factors that require clinical, haematological or biochemical evidence (for example poisoning by specified agents s 9(20); nutritional deficiency s 9(21), s 9(51); chronic renal failure s 9(3), Schedule definition including GFR thresholds), obtain relevant laboratory test results, imaging and specialist letters. The Schedule provides diagnostic content such as the GFR threshold for chronic renal failure and lists of agents that must be demonstrated.

   • For exposures tied to military activities (TCDD contamination activities enumerated in Schedule 1), secure service records, logs, equipment maintenance records, witness statements, or contemporaneous diaries that document the specific activity (spraying, decanting, sawing treated timber, etc.) within the specified 30 day window (ss 9(18), 9(48); Schedule).

6. Use electrodiagnostic testing and specialist neurology reports

   • Because the definition requires signs or electrodiagnostic evidence (s 7(2)(a)(ii)), obtain and include EMG and nerve conduction study reports where available. Specialist neurology statements that interpret those studies and connect them to symptoms will be influential.

7. For death claims, demonstrate contribution to terminal event

   • Where the claim concerns death from peripheral neuropathy, show how the neuropathy materially contributed to the proximate or ultimate cause of death (s 7(3) and Schedule definition of "terminal event"). Provide death certificates, clinicians’ opinions, hospital discharge summaries, and timelines linking neuropathy to terminal events like pneumonia or respiratory failure.

8. Cross‑check for interaction with other SoPs (s 11)

   • If any factor in s 9 references an injury or disease that is itself the subject of a separate SoP, consult that SoP "as in force from time to time" (s 11). Ensure evidence also meets the requirements of the other SoP if reliance is being placed on that disease as the connecting factor.

9. Prepare for disproving alternative causes and the requirement of relation to relevant service (s 10)

   • It is not sufficient merely to show a listed factor; the factor must be related to the person’s relevant service (s 10(1)). Assemble service records, exposure records and contemporaneous medical records that support a link between the factor and relevant service. For aggravation/material contribution in pre‑existing neuropathy, ensure the neuropathy pre‑dated service and that the factors in ss 9(32)-9(62) are demonstrated with the appropriate timing (s 10(2)).

10. Practical documentary checklist

• Clinical notes describing symptoms, signs and onset dates.

• EMG and nerve conduction study reports.

• Specialist neurology letters interpreting tests and providing causation opinion.

• Full medication chart and pharmacy dispensing records, with dates and doses.

• Laboratory and imaging records for biochemical, haematological or toxicology markers.

• Surgical records if relying on bariatric surgery within five years, or transplantation.

• Oncology/chemotherapy records for cisplatin or other suspect agents with timing.

• Service records documenting tasks, exposures and locations.

• Occupational health and safety records for chemical exposures, including measured concentrations where available.

• Death certificate and terminal event documentation for death claims, with clinicians’ causal opinions.

• Addiction medicine or psychiatric assessments for DSM‑5‑TR‑based severe alcohol/substance use disorder.

11. Evidence presentation and sequencing

• Build a clear timeline that aligns disease onset/worsening, service periods, drug exposures, chemical exposures, surgeries and laboratory evidence.

• Where relying on drug cessation/rechallenge evidence under ss 9(24), 9(26), 9(54), 9(56), present the sequence of events (start of drug, onset of neuropathy, cessation or tapering, improvement within three months if that is claimed, and any rechallenge data).

• Address exclusions proactively: if the claimant’s neuropathy might be characterised as an excluded entity under s 7(2)(c), provide evidence explaining why the case falls within this SoP’s definition and not within an excluded category.

12. Monitor other SoPs and the RMA’s updates

• Because s 11 imports other SoPs "as in force from time to time", monitor relevant RMA SoPs for updates that could change evidentiary expectations for cross‑referenced conditions.

Following this compliance pathway aligns evidential production with the instrument’s explicit requirements (ss 7-11; Schedule 1). Success depends on rigorous, contemporaneous documentation and on matching documentary evidence to the precise timing, dose, frequency and diagnostic thresholds the instrument prescribes. Failure to satisfy any of those elements may lead to a decision that the SoP’s listed factors have not been shown to raise a reasonable hypothesis of a service connection.